125 related articles for article (PubMed ID: 35525812)
1. Corrigendum to "AGBL2 promotes cancer cell growth through IRGM-regulated autophagy and enhanced Aurora A activity in hepatocellular carcinoma" [Canc. Lett. 414 (2018) 71-80].
Wang LL; Jin XH; Cai MY; Li HG; Chen JW; Wang FW; Wang CY; Hu WW; Liu F; Xie D
Cancer Lett; 2022 Jul; 539():215700. PubMed ID: 35525812
[No Abstract] [Full Text] [Related]
2. AGBL2 promotes cancer cell growth through IRGM-regulated autophagy and enhanced Aurora A activity in hepatocellular carcinoma.
Wang LL; Jin XH; Cai MY; Li HG; Chen JW; Wang FW; Wang CY; Hu WW; Liu F; Xie D
Cancer Lett; 2018 Feb; 414():71-80. PubMed ID: 29126912
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum to "Circadian clock gene NPAS2 promotes reprogramming of glucose metabolism in hepatocellular carcinoma cells" [Canc. Lett. 469 (2020) 498-509].
Yuan P; Yang T; Mu J; Zhao J; Yang Y; Yan Z; Hou Y; Chen C; Xing J; Zhang H; Li J
Cancer Lett; 2021 Nov; 521():322-323. PubMed ID: 34521548
[No Abstract] [Full Text] [Related]
4. Corrigendum to "NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma" [Canc. Lett. 476 (2020) 48-56].
Leung HW; Lau EYT; Leung CON; Lei MML; Mok EHK; Ma VWS; Cho WCS; Ng IOL; Yun JP; Cai SH; Yu HJ; Ma S; Lee TKW
Cancer Lett; 2021 Feb; 499():2. PubMed ID: 32563702
[No Abstract] [Full Text] [Related]
5. Corrigendum to "MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways" [Canc. Lett. 337 (2013) 226-236].
Bao L; Yan Y; Xu C; Ji W; Shen S; Xu G; Zeng Y; Sun B; Qian H; Chen L; Wu M; Chen J; Su C
Cancer Lett; 2020 Mar; 473():198-199. PubMed ID: 31926781
[No Abstract] [Full Text] [Related]
6. Corrigendum to "Long non-coding RNA Unigene 56159 promotes epithelial-mesenchymal transition by acting as a ceRNA of miR-140-5p in hepatocellular carcinoma cells" [Canc. Lett. 382 (2016) 166-175].
Lv J; Fan HX; Zhao XP; Lv P; Fan JY; Zhang Y; Liu M; Tang H
Cancer Lett; 2020 Mar; 472():181-182. PubMed ID: 31879079
[No Abstract] [Full Text] [Related]
7. Corrigendum to "LncRNA n335586/miR-924/CKMT1A axis contributes to cell migration and invasion in hepatocellular carcinoma cells" [Canc. Lett. 429 (2018) 89-99].
Fan H; Lv P; Mu T; Zhao X; Liu Y; Feng Y; Lv J; Liu M; Tang H
Cancer Lett; 2020 Dec; 494():84-87. PubMed ID: 32911100
[No Abstract] [Full Text] [Related]
8. Corrigendum to "cPLA2α activates PI3K/AKT and inhibits Smad2/3 during epithelial-mesenchymal transition of hepatocellular carcinoma cells" [Canc. Lett. 403 (2017) 260-270].
Fu H; He Y; Qi L; Chen L; Luo Y; Chen L; Li Y; Zhang N; Guo H
Cancer Lett; 2021 Feb; 498():240-241. PubMed ID: 33221059
[No Abstract] [Full Text] [Related]
9. High expression of AGBL2 is a novel prognostic factor of adverse outcome in patients with ovarian carcinoma.
He WP; Wang LL
Oncol Lett; 2019 Nov; 18(5):4900-4906. PubMed ID: 31612000
[TBL] [Abstract][Full Text] [Related]
10. Corrigendum to "Targeting autophagy in cancer stem cells as an anticancer therapy" [Canc. Lett. 393 (2017) 33-39].
Lei Y; Zhang D; Yu J; Dong H; Zhang J; Yang S
Cancer Lett; 2018 Mar; 416():149. PubMed ID: 29307478
[No Abstract] [Full Text] [Related]
11. Corrigendum to "Forkhead box D1 promotes EMT and chemoresistance by upregulating lncRNA CYTOR in oral squamous cell carcinoma" [Canc. Lett. 503 (2021) 43-53].
Chen S; Yang M; Wang C; Ouyang Y; Chen X; Bai J; Hu Y; Song M; Zhang S; Zhang Q
Cancer Lett; 2022 Jul; 537():215688. PubMed ID: 35459579
[No Abstract] [Full Text] [Related]
12. Corrigendum to "miR-371-5p down-regulates pre mRNA processing factor 4 homolog B (PRPF4B) and facilitates the G1/S transition in human hepatocellular carcinoma" [Canc. Lett. 335 (2013) 351-360].
Liu RY; Diao CF; Zhang Y; Wu N; Wan HY; Nong XY; Liu M; Tang H
Cancer Lett; 2021 May; 505():87-90. PubMed ID: 33685752
[No Abstract] [Full Text] [Related]
13. Corrigendum to "Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer" [Canc. Lett. 459(2019)204-215].
Zhang B; Ye H; Ren X; Zheng S; Zhou Q; Chen C; Lin Q; Li G; Wei L; Fu Z; Zhang Y; Hu C; Li Z; Chen R
Cancer Lett; 2022 Nov; 548():215897. PubMed ID: 36050250
[No Abstract] [Full Text] [Related]
14. Corrigendum to "Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B" [Canc. Lett. 535 (2022) 215629].
Liu Y; Zhang Z; Gao X; Ma Q; Yu Z; Huang S
Cancer Lett; 2022 Jul; 539():215701. PubMed ID: 35527117
[No Abstract] [Full Text] [Related]
15. Corrigendum to "SUMOylation of SYNJ2BP-COX16 promotes breast cancer progression through DRP1-mediated mitochondrial fission" [Canc. Lett. 547 (2022) 215871].
Wang M; Wei R; Li G; Bi HL; Jia Z; Zhang M; Pang M; Li X; Ma L; Tang Y
Cancer Lett; 2022 Nov; 549():215923. PubMed ID: 36166936
[No Abstract] [Full Text] [Related]
16. Corrigendum to "Voltage-gated sodium channel Nav1.5 promotes tumor progression and enhances chemosensitivity to 5-fluorouracil in colorectal cancer" [Canc. Lett. 500 (2021) 119-131].
Sui Q; Peng J; Han K; Lin J; Zhang R; Ou Q; Qin J; Deng Y; Zhou W; Kong L; Tang J; Xiao B; Li Y; Yu L; Fang Y; Ding PR; Pan Z
Cancer Lett; 2021 Sep; 516():57-60. PubMed ID: 34091433
[No Abstract] [Full Text] [Related]
17. Retraction notice to "Long non-coding RNA LINC00160 functions as a decoy of microRNA-132 to mediate autophagy and drug resistance in hepatocellular carcinoma via inhibition of PIK3R3" [Canc. Lett. 478 (2020) 22-33].
Zhang W; Liu Y; Fu Y; Han W; Xu H; Wen L; Deng Y; Li K
Cancer Lett; 2022 Nov; 549():215933. PubMed ID: 36216654
[No Abstract] [Full Text] [Related]
18. Corrigendum to "Polypyrimidine tract binding protein 1 promotes lymphatic metastasis and proliferation of bladder cancer via alternative splicing of MEIS2 and PKM." [Canc. Lett. 449 (2019) 31-44].
Xie R; Chen X; Chen Z; Huang M; Dong W; Gu P; Zhang J; Zhou Q; Dong W; Han J; Wang X; Li H; Huang J; Lin T
Cancer Lett; 2021 Mar; 500():292-293. PubMed ID: 33390287
[No Abstract] [Full Text] [Related]
19. Corrigendum to "UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation" [Canc. Lett. 494 (2020) 121-131].
Yin H; Wang X; Zhang X; Zeng Y; Xu Q; Wang W; Zhou F; Zhou Y
Cancer Lett; 2022 Sep; 543():215792. PubMed ID: 35718664
[No Abstract] [Full Text] [Related]
20. Corrigendum to "DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer" [Canc. Lett. 501 224-233].
Moskovich D; Alfandari A; Finkelshtein Y; Weisz A; Katzav A; Kidron D; Edelstein E; Veroslavski D; Perets R; Arbib N; Kadan Y; Fishman A; Lerer B; Ellis M; Ashur-Fabian O
Cancer Lett; 2023 Jun; 563():216196. PubMed ID: 37104919
[No Abstract] [Full Text] [Related]
[Next] [New Search]
